BIOMAT Database Logo BIOMAT Database Logo

Cholinesterase inhibitors and Alzheimer's disease outcomes. 2007

Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams

UI MeSH Term Description Entries
D007326 Institutionalization The caring for individuals in institutions and their adaptation to routines characteristic of the institutional environment, and/or their loss of adaptation to life outside the institution. Institutionalized Persons,Institutionalizations,Institutionalized Person,Person, Institutionalized,Persons, Institutionalized
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors for Alzheimer's disease.
November 1998, Hospital practice (1995),
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
[Cholinesterase inhibitors in Alzheimer's disease].
January 2001, Journal de pharmacie de Belgique,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors stabilize Alzheimer's disease.
January 2000, Annals of the New York Academy of Sciences,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors for Alzheimer's disease.
January 2001, Drugs,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors for Alzheimer's disease.
September 2006, American family physician,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors for Alzheimer's disease.
January 2006, The Cochrane database of systematic reviews,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors for Alzheimer's disease.
October 2002, Lancet (London, England),
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors: cardioprotection in Alzheimer's disease.
January 2014, Journal of Alzheimer's disease : JAD,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
April 2012, Pharmacology & therapeutics,
Angeles Garcia, and Kelli Thompson, and Katherine Zanibbi, and Shannon Geick, and Rachel Adams
Cholinesterase inhibitors in late-stage Alzheimer's disease.
June 2006, The Lancet. Neurology,
Copied contents to your clipboard!